Blood sample
BiologicalBlood sample will be performed
NCT Number: NCT04374175
This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (<2cm), the chances of recovery are very good.
But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case.
Today, there is no any effective means of detection... Blood markers can be a simple means of early detection
Interested in participating?
Request Info18 year and older
All sexes
Observational
CHU Saint-Etienne, Saint-Etienne, France
The purpose of this study is to establish a sero-library in a case-control cohort to assess several potentially useful serum biomarkers, such as adiponectin in the early diagnosis of pancreatic cancer.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
ADENOCARCINOMA GROUP
Inclusion criteria
Exclusion criteria
CONTROL GROUP
Inclusion criteria
Exclusion criteria
Blood sample will be performed
Time frame: Months : 0
Measure by blood sample result Serum adiponectin concentration threshold for which the specificity will be 100% for the diagnosis of pancreatic cancer with a sensitivity of 80%.
Time frame: Months : 0, 3, 6, 9, 12
Measure by blood sample result Threshold for Comparison of diagnostic performance compared to serum adiponectin concentration
Time frame: Month 12
Tumor response and progression rates defined according to RECIST v1.1 criteria according to a serum threshold of the prognostic biomarker to be identified by logistic regression analyzes.
Time frame: Months : 24
Time frame: Months : 24
Time frame: Months : 3, 6, 9, 12
Measure by blood sample result Serum adiponectin concentration to correlate with cancer progression or not.
Contact information is provided by the study sponsor or research team.
Jean-Marc PHELIP, MD-PhD
CONTACT
( 0)477828320 ext. +33
Nicolas WILLIET, MD
CONTACT
(0)477829029 ext. +33
Centre Hospitalier Universitaire de Saint Etienne
Other
Acronym: SERPAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04543071
Adenocarcinoma, Adenocarcinoma of the Pancreas
New York, United States
View Trial DetailsNCT06649474
Adenocarcinoma, Carcinoma
Clermont-Ferrand, France
View Trial DetailsNCT02905578
Adenocarcinoma, Cancer of Pancreas
Iowa City, Iowa, United States
View Trial DetailsNCT03415854
Adenocarcinoma, Carcinoma
Scottsdale, Arizona, United States
View Trial Details